Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Glioblastoma Multiforme

Institut Claudius RegaudSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

354 Active assets in the Glioblastoma Multiforme cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →